Literature DB >> 23150185

Association between high-molecular-weight adiponectin and bone mineral density in hemodialysis patients.

Nobuyuki Amemiya1, Shigeru Otsubo, Yuko Iwasa, Takako Onuki, Kosaku Nitta.   

Abstract

BACKGROUND: Chronic kidney disease-mineral and bone disorder is a regular complication seen in hemodialysis patients and leads to substantial increases in the fracture rate, morbidity, and mortality. Discovered a few years ago, several clinical studies have shown a negative correlation between adiponectin and bone mineral density (BMD) independently of confounding factors. The relationship between adiponectin and bone metabolism in hemodialysis patients has not been fully described yet. We conducted this study to investigate the relationship between serum adiponectin concentration and the BMD in hemodialysis patients.
METHODS: We enrolled 92 hemodialysis patients who were receiving maintenance hemodialysis therapy at Towa Hospital. A peripheral blood sample was obtained, and standard biological data and the serum high-molecular-weight (HMW) adiponectin level were measured. BMD was assessed using dual-energy X-ray absorptiometry scans.
RESULTS: In male hemodialysis patients, BMD was negatively related to age (r = -0.299, P = 0.012), duration of hemodialysis therapy (r = -0.31, P = 0.009), and log [HMW-adiponectin] (r = -0.31, P = 0.009) and positively related to body weight (r = 0.332, P = 0.004) and BMI (r = 0.297, P = 0.013). In female hemodialysis patients, BMD was negatively related to age (r = -0.499, P = 0.018) and log [HMW-adiponectin] (r = -0.46, P = 0.030) and positively related to triglyceride (r = 0.491, P = 0.020).
CONCLUSIONS: HMW adiponectin may affect bone metabolism in both male and female hemodialysis patients.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23150185     DOI: 10.1007/s10157-012-0723-2

Source DB:  PubMed          Journal:  Clin Exp Nephrol        ISSN: 1342-1751            Impact factor:   2.801


  31 in total

1.  Comparison of serum high-molecular weight (HMW) adiponectin with total adiponectin concentrations in type 2 diabetic patients with coronary artery disease using a novel enzyme-linked immunosorbent assay to detect HMW adiponectin.

Authors:  Yoshimasa Aso; Ruriko Yamamoto; Sadao Wakabayashi; Toshihiko Uchida; Kan Takayanagi; Kohzo Takebayashi; Takehiko Okuno; Teruo Inoue; Koichi Node; Takashi Tobe; Toshihiko Inukai; Yasuko Nakano
Journal:  Diabetes       Date:  2006-07       Impact factor: 9.461

2.  Endogenous glucose production is inhibited by the adipose-derived protein Acrp30.

Authors:  T P Combs; A H Berg; S Obici; P E Scherer; L Rossetti
Journal:  J Clin Invest       Date:  2001-12       Impact factor: 14.808

3.  Serum adiponectin and bone mineral density in male hemodialysis patients.

Authors:  S Okuno; E Ishimura; K Norimine; N Tsuboniwa; S Kagitani; K Yamakawa; T Yamakawa; K K Sato; T Hayashi; S Shoji; Y Nishizawa; M Inaba
Journal:  Osteoporos Int       Date:  2011-09-17       Impact factor: 4.507

4.  Adiponectin stimulates RANKL and inhibits OPG expression in human osteoblasts through the MAPK signaling pathway.

Authors:  Xiang-Hang Luo; Li-Juan Guo; Hui Xie; Ling-Qing Yuan; Xian-Ping Wu; Hou-De Zhou; Er-Yuan Liao
Journal:  J Bone Miner Res       Date:  2006-10       Impact factor: 6.741

5.  Adiponectin reduces atherosclerosis in apolipoprotein E-deficient mice.

Authors:  Yoshihisa Okamoto; Shinji Kihara; Noriyuki Ouchi; Makoto Nishida; Yukio Arita; Masahiro Kumada; Koji Ohashi; Naohiko Sakai; Iichiro Shimomura; Hideki Kobayashi; Naoki Terasaka; Toshimori Inaba; Tohru Funahashi; Yuji Matsuzawa
Journal:  Circulation       Date:  2002-11-26       Impact factor: 29.690

6.  Adiponectin increases bone mass by suppressing osteoclast and activating osteoblast.

Authors:  Kazuya Oshima; Akihide Nampei; Morihiro Matsuda; Masanori Iwaki; Atsunori Fukuhara; Jun Hashimoto; Hideki Yoshikawa; Iichiro Shimomura
Journal:  Biochem Biophys Res Commun       Date:  2005-06-03       Impact factor: 3.575

Review 7.  Adiponectin and adiponectin receptors.

Authors:  Takashi Kadowaki; Toshimasa Yamauchi
Journal:  Endocr Rev       Date:  2005-05       Impact factor: 19.871

8.  The relationship between adipokines, osteocalcin and bone quality in chronic kidney disease.

Authors:  Justine Bacchetta; Stéphanie Boutroy; Fitsum Guebre-Egziabher; Laurent Juillard; Jocelyne Drai; Solenne Pelletier; Michel Richard; Anne Charrié; Marie Christine Carlier; Roland Chapurlat; Maurice Laville; Denis Fouque
Journal:  Nephrol Dial Transplant       Date:  2009-06-10       Impact factor: 5.992

9.  Relation between adiponectin and bone mineral density in elderly post-menopausal women: role of body composition, leptin, insulin resistance, and dehydroepiandrosterone sulfate.

Authors:  E Zoico; M Zamboni; V Di Francesco; G Mazzali; F Fantin; G De Pergola; A Zivelonghi; S Adami; O Bosello
Journal:  J Endocrinol Invest       Date:  2008-04       Impact factor: 4.256

10.  Adiponectin is markedly increased in patients with nephrotic syndrome and is related to metabolic risk factors.

Authors:  Carmine Zoccali; Francesca Mallamaci; Vincenzo Panuccio; Giovanni Tripepi; Sebastiano Cutrupi; Saverio Parlongo; Francesco Catalano; Sachiyo Tanaka; Noriyuki Ouchi; Shinji Kihara; Tohru Funahashi; Yuji Matsuzawa
Journal:  Kidney Int Suppl       Date:  2003-05       Impact factor: 10.545

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.